Demand for corrective surgery for astigmatism cleared for takeoff

Article

As the number of premium IOLs grows, along with the demand for cataract surgeries and the population of patients in their mid-50s and 60s, optometrists are poised to take an essential role in preparing patients and performing preoperative testing.

As the number of premium IOLs grows, along with the demand for cataract surgeries and the population of patients in their mid-50s and 60s, optometrists are poised to take an essential role in preparing patients and performing preoperative testing, according to Douglas K. Devries, OD.

IOLs and LRIs used in tandem

Premium IOLs, including toric lenses, make up 10% to 15% of the market, but that number will grow, according to Dr. Devries. As it does, optometrists will increasingly be the key source of information about these IOLs, he said. Currently, two types of toric lenses are on the market: the STAAR Surgical toric and the Alcon AcrySof IQ toric. The STAAR toric comes in 2.00 D and 3.50 D. Alcon's lens has a greater range of power, 1.50 D to 6.00 D.

The pre-op work-up

The preoperative care before astigmatism correction with an LRI or IOL begins with a comprehensive exam, including accurate refraction, manual keratotomy, corneal evaluation (look for presence of guttata, deficient tear syndrome, or blepharitis or meibomian gland disease), and dilated fundus exam.

Pachymetry is also an essential part of the evaluation. It helps ensure that a correction can be made with the excimer laser if the initial procedure doesn't produce the desired outcome, Dr. Devries said. Corneal topography is especially useful on a patient who has an ectatic disorder which, if not identified before surgery, could affect the outcome.

The work-up for a toric IOL should also include a manifest refraction or a history of refraction, including both the amount and axis of cylinder. Also look for pseudoexfoliation; these patients may not be ideal candidates for a toric IOL. Finally, discuss the method of surgery with the patient as well as his or her expectations.

"Patients need to know, at this point, that it's not a perfected science, but in the vast majority of cases, they will get a better visual outcome," Dr. Devries said.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.